Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure

被引：34

作者：

Jaglal, Michael V. ^{[1
]}

Duong, Vu H. ^{[2
]}

Bello, Celeste M. ^{[1
]}

Al Ali, Najla H. ^{[1
]}

Padron, Eric ^{[1
]}

Fernandez, Hugo F. ^{[1
]}

List, Alan F. ^{[1
]}

Lancet, Jeffrey E. ^{[1
]}

Komrokji, Rami S. ^{[1
]}

机构：

[1] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA

[2] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA

来源：

LEUKEMIA RESEARCH | 2014年 / 38卷 / 04期

关键词：

Azanucleoside treatment failure; Antecedent hematological disorders; Cladrabine; Secondary AML; ACUTE MYELOGENOUS LEUKEMIA; INTENSIVE CHEMOTHERAPY; RISK; OUTCOMES; THERAPY; MULTICENTER; ARABINOSIDE; EFFICACY; ANALOGS; AML;

D O I：

10.1016/j.leukres.2013.12.010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

For patients with acute myeloid leukemia from antecedent myelodysplastic syndrome particularly after azanucleoside treatment failure, outcome is poor. Here, we conducted a case-control study in these patients to compare the efficacy of CLAG-M induction (28 patients) versus standard 3 + 7 induction chemotherapy (24 patients). Response rates (p= 0.014) and median overall survival (p= 0.025) were 64% and 202 days (95% CI 37-367 days) versus 29% and 86 days (95% CI 36-136) in the CLAG-M and 3 + 7 cohorts, respectively. Median overall survival was 202 (95% CI 37-367 days) versus 86 days (95% CI 36-136) (p= 0.025), respectively. CLAG-M has encouraging activity in this patient group. (c) 2013 Elsevier Ltd. All rights reserved.

引用

页码：443 / 446

页数：4

共 23 条

[11] Outcome of Patients With Myelodysplastic Syndrome After Failure of Decitabine Therapy [J].

Jabbour, Elias ;

Garcia-Manero, Guillermo ;

Batty, Nicolas ;

Shan, Jenny ;

O'Brien, Susan ;

Cortes, Jorge ;

Ravandi, Farhad ;

Issa, Jean-Pierre ;

Kantarjian, Hagop .

CANCER, 2010, 116 (16) :3830-3834

[12] Decitabine improves patient outcomes in myelodysplastic syndromes - Resuits of a Phase III randomized study [J].

Kantarjian, H ;

Issa, JPJ ;

Rosenfeld, CS ;

Bennett, JM ;

Albitar, M ;

DiPersio, J ;

Klimek, V ;

Slack, J ;

de Castro, C ;

Ravandi, F ;

Helmer, R ;

Shen, LL ;

Nimer, SD ;

Leavitt, R ;

Raza, A ;

Saba, H .

CANCER, 2006, 106 (08) :1794-1803

[13] Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome - Predictive prognostic models for outcome [J].

Kantarjian, H ;

O'Brien, S ;

Cortes, J ;

Giles, F ;

Faderl, S ;

Jabbour, E ;

Garcia-Manero, G ;

Wierda, W ;

Pierce, S ;

Shan, JQ ;

Estey, E .

CANCER, 2006, 106 (05) :1090-1098

[14]

Kornblau SM, 1996, LEUKEMIA, V10, P1563

[15] Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure [J].

Prebet, Thomas ;

Gore, Steven D. ;

Thepot, Sylvain ;

Esterni, Benjamin ;

Quesnel, Bruno ;

Rauzy, Odile Beyne ;

Dreyfus, Francois ;

Gardin, Claude ;

Fenaux, Pierre ;

Vey, Norbert .

BRITISH JOURNAL OF HAEMATOLOGY, 2012, 157 (06) :764-766

[16] Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure [J].

Prebet, Thomas ;

Gore, Steven D. ;

Esterni, Benjamin ;

Gardin, Claude ;

Itzykson, Raphael ;

Thepot, Sylvain ;

Dreyfus, Francois ;

Rauzy, Odile Beyne ;

Recher, Christian ;

Ades, Lionel ;

Quesnel, Bruno ;

Beach, C. L. ;

Fenaux, Pierre ;

Vey, Norbert .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (24) :3322-3327

[17] Mechanisms of Resistance to Decitabine in the Myelodysplastic Syndrome [J].

Qin, Taichun ;

Castoro, Ryan ;

El Ahdab, Samih ;

Jelinek, Jaroslav ;

Wang, Xiaodan ;

Si, Jiali ;

Shu, Jingmin ;

He, Rong ;

Zhang, Nianxiang ;

Chung, Woonbok ;

Kantarjian, Hagop M. ;

Issa, Jean-Pierre J. .

PLOS ONE, 2011, 6 (08)

[18] Outcomes of Patients Who Undergo Aggressive Induction Therapy for Secondary Acute Myeloid Leukemia [J].

Rizzieri, David A. ;

O'Brien, Jenny A. ;

Broadwater, Gloria ;

Decastro, Carlos M. ;

Dev, Prakash ;

Diehl, Louis ;

Beaven, Anne ;

Lagoo, Anand ;

Gockerman, Jon P. ;

Chao, Nelson J. ;

Moore, Joseph O. .

CANCER, 2009, 115 (13) :2922-2929

[19] Purine nucleoside analogues in the treatment of myleoid leukemias [J].

Robak, T .

LEUKEMIA & LYMPHOMA, 2003, 44 (03) :391-409

[20] Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study [J].

Slovak, ML ;

Kopecky, KJ ;

Cassileth, PA ;

Harrington, DH ;

Theil, KS ;

Mohamed, A ;

Paietta, E ;

Willman, CL ;

Head, DR ;

Rowe, JM ;

Forman, SJ ;

Appelbaum, FR .

BLOOD, 2000, 96 (13) :4075-4083

← 1 2 3 →